Phase 1/2 Study of Intratumoral G100 With or Without Pembrolizumab or Rituximab in Patients with Follicular Non-Hodgkin's Lymphoma
This research study is a Phase 1/2 clinical trial of an investigational agent called G100. The use of G100 for follicular lymphoma (FL) is experimental. It has not been approved by the Food and Drug Administration (FDA) because not enough is known about it. G100 is a new agent that when injected into your tumor can stimulate your body’s immune system to react to your cancer. This immune response may then attack your cancer and stop it from growing.
There are two parts to the study. One part of this study will evaluate the effects, good or bad, of G100 in combination with pembrolizumab. Pembrolizumab is a treatment already approved for other types of cancer but is not currently approved to treat follicular lymphoma. The other part of the study will evaluate the effects, good or bad, of G100 in combination with rituximab. Ritixuximab is a treatment already approved for your type of cancer.
Follicular Non-Hodgkin's Lymphoma
- Men and women at least 18 years of age
- Diagnosed with Follicular Non-Hodgkin's Lymphoma and have not yet received any treatment for it, or you are relapsed or refractory following at least one prior treatment
- Tumor mass(es) accessible for intratumoral injection and being considered for local radiation therapy and at least one additional site of disease outside the radiation field for assessment of distal (abscopal) response
18 - 99
Healthy Volunteers Needed
Duration of Participation
The initial treatment phase will last 11 weeks. There is also an optional additional 11 weeks of treatment. After treatment has completed, there will be long-term follow-up visits every 8 weeks.
Clinical Trials Information Line